

A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin

Authors: Juan Kou¹, Yingying Zhang¹, Feng Zhou¹, Cornelia Sindermann², Christian Montag², Benjamin Becker¹, Keith M Kendrick^{1*}

Affiliations:

¹The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, China.

²Department of Molecular Psychology, Institute of Psychology and Education, Ulm University, Ulm, Germany.

*Corresponding author: Keith M. Kendrick

Institute: The Clinical Hospital of Chengdu Brain Science, MOE Key Laboratory for NeuroInformation

University: University of Electronic Science and Technology of China,

Street Name & Number: No. 2006, Xiyuan Ave, West Hi-tech Zone, Chengdu, 611731, China.

Tel: 86-28-83201358. Fax: 86-28-83201358.

E-mail: kkendrick@uestc.edu.cn

Word count: Abstract (212) Main part (5168)

23 **Abstract**

24 **Background.** The neuropeptide oxytocin is proposed as a promising therapy for social
25 dysfunction by modulating amygdala-mediated social-emotional behavior. Although
26 clinical trials report some benefits of chronic treatment it is unclear whether efficacy
27 may be influenced by dose frequency or genotype.

28 **Methods.** In a randomized, double blind, placebo-controlled pharmaco-fMRI trial (150
29 male subjects) we investigated acute and different chronic (every day or on alternate
30 days for 5 days) intranasal oxytocin (24IU) effects and oxytocin receptor
31 genotype-mediated treatment sensitivity on amygdala responses to face emotions. We
32 also investigated similar effects on resting state functional connectivity between the
33 amygdala and prefrontal cortex.

34 **Results.** A single dose of oxytocin reduced amygdala responses to all face emotions
35 but for threatening (fear and anger) and happy faces this effect was abolished after daily
36 doses for 5 days but maintained by doses given every other day. The latter dose regime
37 also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects
38 on reducing amygdala responses to face emotions only occurred in AA homozygotes of
39 rs53576 and A carriers of rs2254298. The effects of oxytocin on resting state functional
40 connectivity were not influenced by either dose-frequency or receptor genotype.

41 **Conclusions.** Infrequent chronic oxytocin administration may be therapeutically most
42 efficient and its anxiolytic neural and behavioral actions are highly genotype-dependent
43 in males.

Introduction

Intranasal oxytocin (OT) has been proposed as novel treatment to attenuate social dysfunctions and anxiety in autism spectrum disorder, social anxiety and schizophrenia (Kendrick et al., 2017; Meyer-Lindenberg et al., 2011; Young and Barrett, 2015) as well as an augmentative strategy to facilitate fear extinction (Eckstein et al., 2015) and working memory performance (Zhao et al., 2018). Following an initial landmark study in humans demonstrating that OT reduces amygdala responses to threatening (fear and angry) face stimuli (Kirsch et al., 2005), subsequent preclinical research has consistently reported that its effects on amygdala function (attenuated fear reactivity and increased amygdala-prefrontal intrinsic connectivity - Domes et al., 2007; Eckstein et al., 2017; Kendrick et al., 2017; Meyer-Lindenberg et al., 2011; Quintana et al., 2016; Spengler et al., 2017; Sripada et al., 2013; Wang et al., 2017) may represent its primary therapeutic-relevant neural mechanism of action.

The proposed neural mechanisms of OT have been established using acute single dose administration protocols, with a dose-response study demonstrating 24 International Units (IU) as optimal for reducing amygdala responses to fear stimuli using conventional intranasal spray devices (Spengler et al., 2017). To date however, no human studies have demonstrated whether chronic treatment protocols can produce enhanced functional effects and initial clinical trials using chronic (twice daily) administration over periods of a week or longer have reported inconsistent, or at best

66 modest therapeutic efficacy on social-emotional dysfunctions (Guastella et al., 2015;
67 Halverson et al., 2019; Jarskog et al., 2017; Kendrick et al., 2017; Watanabe et al.,
68 2015; Yamasue et al., 2018).

69 G-protein-coupled neuropeptide receptors typically exhibit internalization
70 following even a relatively short period of constant exposure to their target peptides
71 and cannot subsequently respond (desensitized) until they are recycled back the
72 surface of the cell membrane (Pierce et al., 2002; Lohse and Hofmann, 2015).
73 Growing evidence from both in vitro and animal studies suggest there may be
74 extensive internalization and subsequent desensitization of OT receptors (OXTR)
75 following repeated OT administration (Smith et al., 2006; Stoop, 2012). In terms of
76 neural OXTR receptors those in the amygdala may be particularly susceptible to
77 desensitization (Terenzi and Ingram, 2005) and this region critically mediates many of
78 the effects of intranasal OT on social cognition and anxiety (Kendrick et al., 2017).
79 Moreover, rodent models have reported that in contrast to single doses, chronic
80 administration of OT can actually produce social impairment (Bales et al., 2013; Du
81 et al., 2017; Huang et al., 2014) in the context of reduced receptor expression in the
82 amygdala and nucleus accumbens (Du et al., 2017). Furthermore, an initial study
83 reported that chronic versus single administration of OT results in divergent
84 neurochemical changes in both the rodent and human frontal cortex (Benner et al.,
85 2018), emphasizing high translational relevance of the preclinical animal models for
86 clinical trials employing chronic treatment protocols. Thus, empirically evaluated

87 optimal treatment protocols for chronic intranasal OT administration in humans are
88 urgently needed to determine its therapeutic potential.

89 A further unresolved issue is that different OT receptor (OXTR) genotypes have
90 been associated with social behaviors and may influence sensitivity of behavioral and
91 neural responses to intranasal OT. In particular, OXTR polymorphisms rs53576 and
92 rs2254298 have been associated with autism (Cataldo et al., 2018), deficits in social
93 and emotional processing and anxiety (Jurek and Neumann, 2018; Parker et al., 2014;
94 Yang et al., 2017) and individual variations in behavioral and neural responses to
95 intranasal OT (Chen et al., 2015; Feng et al., 2015). Indeed, variants of rs2254298
96 may represent a trans-diagnostic biomarker for social dysfunctions (Brüne, 2012). It is
97 therefore imperative to establish whether OXTR polymorphisms could influence
98 sensitivity to effects of intranasal OT.

99 While single doses of OT can produce numerous functional effects, two of key
100 importance are attenuated amygdala responses to face emotions, particularly fear, and
101 increased resting state functional connectivity between the amygdala and prefrontal
102 cortex (Domes et al., 2007; Eckstein et al., 2017; Kirsch et al., 2005; Koch et al., 2016;
103 Quintana et al., 2016; Spengler et al., 2017; Sripada et al., 2013). While most task
104 studies have focused on the effects of OT on amygdala responses to fear faces using a
105 variety of different task paradigms some studies have reported valence independent
106 effects of OT (Domes et al., 2007; Koch et al., 2016; Quintana et al., 2016). Both
107 these task and resting state neural markers have been primarily associated with

attenuated anxiety in terms of reduced responses to social threat and enhanced top-down control of emotion (Zhao et al., 2019), although effects of OT on the amygdala may influence a range of social cognition domains (Kendrick et al., 2017; Meyer-Lindenberg et al., 2011; Young and Barrett, 2015).

To help determine optimal treatment protocols for chronic intranasal OT administration the current pre-registered double-blind, randomized between subject placebo (PLC)-controlled pharmacological neuroimaging trial therefore aimed to replicate previous findings for effects of a single dose of OT (24IU) on reduced amygdala responses to fear or other face emotions (Domes et al., 2007; Kirsch et al., 2005; Koch et al., 2016; Quintana et al., 2016; Spengler et al., 2017; Wang et al., 2017) in a large sample at the whole brain level and on increasing resting-state functional connectivity between the amygdala and prefrontal cortex (Eckstein et al., 2017; Sripatha et al., 2013). Next, the primary outcome of the trial was to establish whether different repeat dosing protocols (daily, OT₅ group, or every other day, OT₃ group, for 5 days) modulate amygdala-centered neural and behavioral responses and resting state functional connectivity. As a secondary outcome, we further aimed to establish if effects of OT on primary outcome measures were influenced by OXTR genotype, focusing on the rs53576 and rs2254298 polymorphisms most frequently associated with social function and individual variations in intranasal OT sensitivity.

Material and Methods

The main study objectives were to investigate both the effects of acute (single dose) and repeated doses (daily or every other day for 5 days) of 24IU OT versus PLC on two primary outcomes: (1) amygdala and behavioral responses to face emotions (particularly fear faces) and (2) resting state functional connectivity between the amygdala and frontal cortex. We investigated modulatory influences of OXTR rs53576 and rs2254298 polymorphisms on the sensitivity to intranasal OT as a secondary outcome.

Participants

A total of 150, right-handed healthy adult male subjects were enrolled according to common inclusion and exclusion criteria for human OT-administration studies (see SI). Given that methods for estimating power for whole brain task-based fMRI analyses are limited (Poldrack et al., 2017), subject number was initially chosen on the basis of recent large-scale studies investigating dose effects of OT (Spengler et al., 2017 n = 111 males; Lieberz et al., 2019, 90 females). A priori power estimates for behavioral analyses were calculated using Webpower (Zhang and Yuan, 2018) giving a range of 60-80% power for ANOVA main and interaction effects and post-hoc tests. For full details see SI. Calculating power for fMRI experiments is more problematic and likely to be much lower, although since the amygdala was our only pre-registered ROI of interest, and the majority of fMRI post-hoc analyses used a single amygdala ROI, this avoids the problem of significantly reduced power when undirected whole brain analyses are performed (see Cremers et al., 2017). The current chosen sample

size is also comparable to the previous largest fMRI studies investigating task-related effects of OT (Spengler et al., 2017; Lieberz et al., 2019). Three subjects failed to meet inclusion criteria (were currently taking medications) and 9 subjects were excluded due to failure to complete the study or excessive head movement (see **Fig. S1**). Subjects were randomly (computer-generated randomization) assigned to repeated intranasal treatment (single daily dose on five consecutive days) of (1) placebo (PLC; $n = 46$, $M \pm SD$, 22.46 ± 2.3 years), (2) oxytocin (OT₅; $n = 49$, $M \pm SD$, 21.78 ± 2.3 years), or interleaved OT and PLC (OT on days 1, 3, 5, PLC on days 2, 4; OT₃; $n = 43$, $M \pm SD$, 21.02 ± 2.0 years) (see **SI**). To ensure compliance all subjects were supervised during self-administration of all nasal sprays. Groups did not differ on a number of potential confounders (see **SI** and **Table S4**). The study was approved by the local ethics committee (Institutional Review Board, University of Electronic Science and Technology of China) and subjects provided written informed consent. The study was in accordance with the latest revision of the Declaration of Helsinki, pre-registered at Clinical Trials.gov (NCT03610919 - <https://clinicaltrials.gov/ct2/show/NCT03610919>) and in line with recommendations for trials in psychological experiments (Guidi et al., 2018) (see **Fig. S1** for Consort flow diagram). Subjects received 500 RMB monetary compensation for participation.

Experimental procedures

The study employed a double-blind, randomized, placebo-controlled, between-subject design. The OT and PLC sprays used in the 3 groups were supplied by Sichuan Meike

Pharmaceutical Co. Ltd, Sichuan, China in identical dispenser bottles containing identical ingredients (glycerine and sodium chloride) other than OT. In line with recommended guidelines experiments started 45 minutes after intranasal administration (Guastella et al., 2013). Recent studies have confirmed that intranasal OT enters the brain (Lee et al 2018), increases cerebrospinal fluid and blood concentrations (Striepens et al., 2013) and produces activity changes in brain regions expressing OXTRs in humans at around 45 minutes after administration (Paloyelis et al., 2016; Quintana et al 2019). In post-treatment interviews on days 1 and 5 subjects could not identify better than chance whether they had received OT or PLC ($\chi^2 < 0.1$, $p > 0.2$, **Table S4**). For OXTR genotyping subjects provided buccal swaps on the 1st day for analysis of OXTR rs2254298, rs53576 SNPs (see **SI** and (Montag et al., 2017)).

For the implicit face-emotion processing task 208 grayscale facial stimuli displaying happy, neutral, angry or fearful facial expressions (n = 26 per category, 50% female) were used (two different stimulus sets - see **SI** for details).

Primary outcomes and analysis plan

Face emotion-related amygdala responses were assessed using the event-related implicit face processing fMRI paradigm on treatment days 1 and 5. Intrinsic amygdala connectivity was assessed by means of resting state fMRI assessments before the task-paradigm. Valence, arousal and intensity ratings (scale: 1-9) for the facial stimuli were collected immediately after MRI acquisition as additional behavioral outcomes

(further details see **SI**). In line with the main aim of the study changes in amygdala face emotion reactivity and amygdala intrinsic connectivity between the 1st and 5th day served as primary outcome measures. Changes in valence, arousal and intensity ratings for the different face emotions represented an associated behavioral outcome measure.

Imaging acquisition and analysis

Blood oxygenation level-dependent contrast functional images were acquired using standard sequences on a 3T GE MR750 system. High resolution T1-weighted structural MRI data were acquired on both 1st and 5th days to improve normalization. MRI data was preprocessed using validated procedures in SPM12 (Friston et al., 1994) (Statistical Parametric Mapping; <http://www.fil.ion.ucl.ac.uk/spm>) and Data Processing Assistant or Resting-State fMRI (Yan, 2010) (DPARSFA; <http://rfmri.org/DPARSF>) (for details see **SI**). First level General Linear Models (GLM) for the task-related fMRI data included separate regressors for the four emotional conditions, gender identity rating period and 6 movement parameters and appropriate contrasts were subjected to a second level random effects analysis.

Primary outcomes: The effects of OT on amygdala and behavioral face emotion reactivity and intrinsic connectivity

Differences in amygdala and behavioral responses to face emotions were examined using mixed ANOVAs with treatment group (PLC, OT₃, OT₅) as between-subject and time point (1st and 5th days) and face emotion (angry, fear, happy and neutral) as

within-subject factors. Dependent variables were extracted target region amygdala responses using the template of left and right amygdala masks from the Brainnetome atlas (Fan et al., 2016) to faces (parameter estimates extracted using Marsbar, <http://marsbar.sourceforge.net>) and valence, intensity and arousal ratings. Post-hoc comparisons explored significant interactions for amygdala and behavioral ratings. Associations between amygdala responses and behavioral ratings were assessed using Pearson correlation.

Differences in resting state amygdala functional connectivity were determined using a voxel-wise seed-to-whole-brain ANOVA as implemented in the SPM flexible factorial design with treatment (PLC, OT₃, OT₅) as between-subject and time point (1st and 5th days) as within-subject factors and amygdala connectivity maps as dependent variable. (See data analysis flow chart in SI)

Secondary outcome measures: influence of OXTR genotype

For rs2254298 subjects were divided into A carriers (AA and AG) and A non-carriers (GG) and rs53576 into G carriers (GG and GA) and G non-carriers (AA). To explore effects of genotype as a secondary outcome measure, OXTR group was included as an additional between-subject factor in the corresponding ANOVAs and amygdala reactivity to face emotions, amygdala-prefrontal cortex intrinsic functional connectivity and behavior rating response served as dependent variables.

Control for treatment effects on brain structure

To control for potential confounding effects of single- and repeated OT-administration on brain structure, a voxel-based morphometry (VBM) analysis was conducted on the T1-weighted images acquired on both testing days using SPM12 standard procedures (Ashburner, 2007; Ashburner and Friston, 2005)(see **SI**).

Thresholding and statistical implementation

In line with our regional hypothesis the analysis of the implicit emotional face task focused on the amygdala. To account for the complex design of the trial we employed two analytic approaches: (1) A region of interest analysis (ROI) on the extracted beta estimates from atlas-based masks for the left and right amygdala (Brainnetome Atlas, Fan et al., 2016) respectively. To this end the extracted estimates were subjected to three-way ANOVAs (treatment \times time point \times face emotion) examining effects on the left and right amygdala separately. The p-value for the analysis was adopted to $p < 0.025$ (Bonferroni corrected multiple comparison $0.05/2$). (2) To facilitate a more specific localization of the effects and to determine a more specific seed mask for the seed-to-whole brain resting state functional connectivity analysis a voxel-wise small volume corrected (SVC) analysis for the entire bilateral amygdala was additionally employed. To this end a peak-level Family-wise error (FWE) small volume correction was applied to a single mask encompassing the bilateral amygdala as provided in the Brainnetome Atlas (Fan et al., 2016) (total volume of the mask, 4572.27mm^3) (FWE $p < .05$). For the seed-to-whole brain resting state data analysis a whole-brain cluster-based FWE-correction with an initial cluster forming threshold of $p < .001$ and

FWE $p < .05$ was employed. Behavioral and neural (extracted parameter estimates) indices were further analyzed using SPSS 22.0 with appropriate ANOVA models and Bonferroni corrected post-hoc tests. $P < 0.05$ two-tailed was considered significant. Partial eta squared (η^2_p) and Cohen's d were computed for behavioral results as measures of effect size and SPSS outlier analysis was used to confirm the absence of statistical outliers. Full details of the post-hoc and correlation analyses are provided in the SI (Tables S7 – S11).

Results

Primary outcome measure: ROI analysis of acute and repeated doses on OT-evoked changes in amygdala responses to face emotions

Examination of the extracted parameter estimates from the amygdala (a priori ROI approach in accordance with trial pre-registration) revealed a significant three-way ANOVA for the right amygdala ($F_{(6,405)}=2.563$; $p<0.019$), but not the left amygdala ($F_{(6,405)}=1.860$; $p=0.087$). Post-hoc analyses on the extracted beta values from the right amygdala mask on the 1st day revealed that both OT groups compared to PLC exhibited a suppression of right amygdala reactivity (fear: $ps < 0.015$, angry: $ps < 0.016$; happy: $ps < 0.041$; neutral: $ps < 0.017$). Analysis on the 5th day revealed that the OT₃ group exhibited a suppression of right amygdala reactivity to fear and angry faces relative to both the PLC (fear: $p = 0.003$, angry: $p = 0.008$) and OT₅ groups (fear: $p = 0.021$; angry: $p = 0.082$) but the OT₅ group did not ($ps > 0.315$, relative to PLC group). The OT₃ group also exhibited reduced right amygdala reactivity to happy

faces on the 5th day compared with the PLC group ($p = 0.028$) but there was no significant difference between OT₃ and OT₅ groups ($p = 0.272$). There were no significant effects of OT on the 5th day for neutral faces ($p > 0.203$, although OT₃ vs PLC was marginal, $p = 0.052$). While amygdala reactivity to fear faces did not differ in the PLC group between days 1 and 5 ($p = 0.356$), its reduction in the OT₃ group on day 5 was equivalent to day 1 ($p = 0.538$) whereas in the OT₅ group the reduction on day 5 was significantly less than on day 1 ($p = 0.035$). Amygdala reactivity to angry faces decreased significantly more in the OT₃ group on day 5 relative to day 1 ($p = 0.006$), although it also did so in the PLC group for both angry ($p = 0.007$) and neutral ($p = 0.028$) (**Fig. 1b-e**).

Primary outcome measure: behavioral rating analysis of acute and repeated doses to face emotions

Mixed ANOVAs on the behavioral data revealed a significant main effect of treatment group on arousal ratings (arousal: $F_{2, 135} = 5.06$, $p = 0.008$, $\eta^2_p = 0.07$) due to ratings generally being lower in the OT₃ group. There was also a marginal significant treatment group x time point x face emotion interaction effect for arousal ($F_{6, 405} = 1.83$, $p = 0.093$, $\eta^2_p = 0.03$) and a significant one for intensity ($F_{6, 405} = 3.327$, $p = 0.004$, $\eta^2_p = 0.05$). Post-hoc analysis showed that intensity ratings were significantly reduced for fear faces in the OT₃ group on the 5th day (fear: $p = 0.004$ versus PLC, $d = 0.62$, 95% CI, -1.299 to -0.247, $p = 0.088$ versus OT₅, $d = 0.33$, 95% CI, -0.968 to 0.068). Exploratory post-hoc analysis of arousal ratings revealed a similar reduction

to fear faces on day 5 ($p = 0.001$ versus PLC, $d = 0.77$, 95% CI, -1.544 to -0.420, $p = 0.033$ versus OT₅, $d = 0.42$, 95% CI, -1.158 to -0.051). Arousal ratings to fear faces were also decreased in the OT₃ group on the 1st day compared to the PLC group but not the OT₅ group (arousal: $p = 0.015$ versus PLC, $d = 0.60$, 95% CI, 0.129 to 1.175, $p = 0.355$ versus OT₅, 95% CI, -0.268 to 0.744). Arousal and intensity ratings to angry faces were reduced on day 5 compared with day 1 in the OT₃ (arousal: $p = 0.001$, $d = 0.30$, 95% CI, 0.164 to 0.619, intensity: $p = 0.001$, $d = 0.32$, 95% CI, 0.173 to 0.641) and OT₅ groups (arousal: $p = 0.023$, $d = 0.19$, 95% CI, 0.032 to 0.461, intensity: $p = 0.006$, $d = 0.26$, 95% CI, 0.088 to 0.526). There were no significant differences for angry, neutral and happy faces between OT and PLC groups on the 1st day ($ps > 0.194$, although OT₅ vs PLC was marginal, $p = 0.051$ for neutral faces) and 5th day ($ps > 0.671$, although OT₃ vs PLC $p = 0.053$ was marginal for angry faces). There was however a significant group difference between OT₃ and OT₅ on the 1st and 5th day for happy and neutral faces ($ps < 0.007$) (**Fig.2**). While there was a significant 3-way interaction for valence ratings ($F_{6, 405} = 2.63$, $p = 0.016$, $\eta^2_p = 0.04$), post-hoc analysis revealed no significant differences between OT and PLC groups on the 1st ($ps > 0.200$) or 5th days ($ps > 0.173$).

The whole brain voxel based morphometry analysis revealed no significant effects of acute or repeated doses of OT on gray matter volumes.

Associations between amygdala responses and behavioral ratings to emotional faces

Associations between right amygdala activation (extracted parameter estimates from the right amygdala mask as provided by the Brainnetome atlas) and emotional arousal and intensity scores to fear faces were observed in the PLC group on the 1st day (arousal: $r = 0.295$, $p = 0.023$; intensity: $r = 0.455$, $p = 0.001$) demonstrating that greater amygdala activation in response to fear faces was associated with increased anxiety. This association was absent in both OT groups on the 1st day (arousal: OT₃, $r = 0.041$, $p = 0.398$; OT₅, $r = 0.050$, $p = 0.366$; intensity: OT₃, $r = 0.098$, $p = 0.265$; OT₅, $r = 0.164$, $p = 0.130$). A similar trend occurred on the 5th day (arousal: PLC, $r = 0.306$, $p = 0.019$; OT₃, $r = -0.011$, $p = 0.471$; OT₅ group, $r = -0.120$, $p = 0.206$; intensity: PLC, $r = 0.212$, $p = 0.079$; OT₃, $r = -0.108$, $p = 0.246$; OT₅ group, $r = -0.043$, $p = 0.385$) (**Fig.3**). There was a similar relationship with responses to angry faces for intensity but not arousal ratings in the PLC group on the 1st day. (arousal: $r = 0.107$, $p = 0.240$; intensity: $r = 0.297$, $p = 0.023$). No associations were found for responses to neutral or happy faces.

Primary outcome measure: effects of acute and repeated oxytocin doses on resting-state functional connectivity

To facilitate a more precise localization of the coordinates of amygdala for the resting state analysis a voxel-wise mixed ANOVA with treatment group (PLC, OT₃, OT₅) as between-subject, time point (1st and 5th days) and face emotion (happy, neutral, angry and fear) as within-subject factor was computed on the task-based data. This analysis revealed a significant three-way interaction effect in the right amygdala after small

volume correction for the bilateral mask encompassing the entire amygdala ($k = 7$,
 $p_{FWE} = 0.021$, $F_{6,405} = 4.47$, peak MNI co-ordinate: $x=18$, $y=-7$, $z=-16$) (**Fig.4a**)
confirming the findings from the ROI analysis which revealed a significant interaction
effect for the right amygdala only. An amygdala seed-to-whole brain fMRI
resting-state analysis employing this region as seed (6 radius sphere centered at $x=18$,
 $y=-7$, $z=-16$) by mixed-effect ANOVA revealed a main effect of treatment (OT₃, OT₅
and PLC) on amygdala functional coupling with the anterior prefrontal cortex (peak
MNI coordinate $x = -3$, $y = 53$, $z = -19$, $F_{2, 135} = 16.55$, $p_{FWE} = 0.001$, $k = 88$) (see Fig.
4a) but no treatment group x time point interaction. Right amygdala intrinsic
connectivity with the prefrontal cortex was stronger in both the OT₃ ($k = 74$, $p_{FWE} =$
 0.014 , $x = -3$, $y = 53$, $z = -19$) and OT₅ groups ($k = 127$, $p_{FWE} = 0.001$, $x = -3$, $y = 53$,
 $z = -19$) relative to PLC. The OT₃ and OT₅ groups did not differ significantly on the
1st ($p = 0.147$) or 5th ($p = 0.107$) days (see Fig. 4b). Correlation analysis revealed no
significant association between resting state and amygdala task-related changes
($r = -0.08$, $p = 0.59$ in PLC group) or behavioral ratings of emotional faces
($-0.085 < r_s < 0.055$, $p_s > 0.57$).

Secondary outcome measure: Associations between OT-effects and OXTR genotype

The number of G-carriers and G-non-carriers of rs53576 and A-carriers and
A-non-carriers of rs2254298 did not differ between the three groups and both SNPs
satisfied Hardy Weinberg Equilibrium (see **Tables S2 and S3**). A four-way mixed

ANOVA with treatment group and genotype as between- and time point and face emotion as within-subject factors revealed significant treatment x genotype interactions for both rs2254298 and rs53576 (rs 2254298: $F_{2, 105} = 3.17$, $p = 0.046$, rs53576: $F_{2, 105} = 3.23$, $p = 0.044$) for amygdala responses to emotional faces, although they would not survive a Bonferroni correction for 4 genotypes (i.e. $p < 0.0125$). Post-hoc analysis showed that reduced amygdala reactivity to emotional faces in both OT groups occurred in A-carriers of rs2254298 ($ps < 0.009$) but not A-non-carriers ($ps > 0.587$) and G-non-carriers of rs 53576 ($ps < 0.002$) but not G-carriers ($ps > 0.196$) (see Fig. 5a-b). For behavioral ratings there were significant treatment group x genotype interactions for both arousal and intensity ratings for rs2254298 (arousal: $F_{2, 105} = 6.60$, $p = 0.002$, $\eta^2_p = 0.11$; intensity: $F_{2, 105} = 3.85$, $p = 0.024$, $\eta^2_p = 0.07$). Post-hoc analysis showed that decreased ratings for faces in the OT₃ group only occurred in A-carriers (arousal: versus PLC: $p = 0.002$, $d = 4.68$, 95% CI, 0.363 to 1.524 and OT₅ $p < 0.001$, $d = 6.56$, 95% CI, 0.743 to 1.904; intensity: PLC: $p = 0.021$, $d = 3.40$, 95% CI, 0.109 to 1.301; OT₅: $p = 0.003$, $d = 4.40$, 95% CI, 0.314 to 1.507). No significant main or interaction effects involving treatment and genotype were found for resting state functional connectivity between amygdala and prefrontal cortex (rs 2254298 all $ps > 0.123$; rs53576 all $ps > 0.566$).

Discussion

Overall, our findings validate OT-reductions in amygdala responses to face emotions and associated emotional intensity and arousal ratings for fear faces, together with

increased resting state functional connectivity between the amygdala and prefrontal cortex as robust markers for its putative therapeutic mechanisms of action. While, these task-dependent and resting-state effects of OT show a different sensitivity to repeated intranasal doses and OXTR genotype our findings indicate that to achieve maximal effects of chronic treatment on neural and behavioral responses to face emotion stimuli and resting-state changes the optimal protocol may be to administer 24IU doses every other day rather than daily.

Our findings are highly consistent with preclinical animal models demonstrating OXTR desensitization following repeated doses of OT in some brain regions (Terenzi and Ingram, 2005; Smith et al., 2005; Stoop, 2012) and that chronic administration can reduce brain OXTR expression (Du et al., 2017) and alter patterns of neurochemical release (Benner et al., 2018). Importantly, chronic doses of OT in rodents fail to produce anxiolytic effects normally seen with single doses (Du et al., 2017) which mirrors our present observations. The apparent long-lasting desensitization effects of daily OT administration on amygdala responses to threatening and happy faces may be contributed to by dose magnitude and so possibly lower daily doses might be less problematic. We also observed some evidence for reduced amygdala and behavioral responses to repeated emotional face presentations in the PLC group in line with previous observations (Fischer et al., 2003; Wright et al., 2001), even though different sets of face stimuli were used at the two time-points. This may have served to reduce time-dependent effects of OT to some extent.

The amygdala is one of the main neural substrates mediating OT's functional effects and its attenuation of reactivity to threatening stimuli is considered as a putative primary therapeutic mechanism of action (see Jurek and Neumann, 2018; Kendrick et al., 2017; Neumann and Slattery, 2016). However, in the current study we demonstrated similar effects of OT in reducing right amygdala responses to all emotional faces, although desensitization effects were only significant for threatening (fear and anger) and happy faces. While some previous studies have found effects of OT only for fear faces (Spengler et al., 2017) or for fear and angry ones (Kirsch et al., 2005), our current findings are in agreement with a number of others reporting that it can reduce amygdala responses to both positive and negative (Domes et al., 2007) or all face emotions (Koch et al., 2016; Quintana et al., 2016). A possible explanation for these differences could be that studies, including our own, using presentation strategies where subjects are not directly required to identify or discriminate between face emotions (Domes et al., 2007; Koch et al., 2016; Quintana et al., 2016) have tended to report valence-independent results. Importantly however, only the magnitude of amygdala responses to fear faces was positively associated with arousal and intensity ratings in the PLC group and OT exerted an anxiolytic action by both reducing these ratings and abolishing their correlation with amygdala activation. Dysregulations in amygdala and behavioral responses to threatening stimuli have been observed across major psychiatric disorders, particularly those characterized by marked social impairments and anxiety (Hennessey et al., 2018; Neumann and Slattery, 2016). There was some evidence that behavioral anxiolytic effects of OT

were greater after repeated compared to single doses in the group receiving OT every other day for angry faces but not in terms of amygdala responses. Possibly the short 5 day period for OT-treatment was not sufficient to demonstrate robust enhancement effects of repeated doses and time-dependent enhancement effects of longer duration treatment need to be investigated in studies on clinical populations.

A major finding from our secondary outcome measure is that OT's attenuations of neural and behavioral responses to face emotions are highly dependent on OXTR genotype. Only G non-carriers of rs53576 and A-carriers of rs2254298 showed significant reductions in amygdala responses to face emotions under OT although only A-carriers of rs2254298 showed evidence for significant reductions in arousal and intensity ratings. A-carriers of both SNPs have frequently been associated with social dysfunction in autism and social anxiety disorders (Cataldo et al., 2018; Jurek and Neumann, 2018). A recent haplotype-based analysis of OXTR SNPs including rs53576 and rs2254298 also indicated an association with sensitivity to OT-effects on face recognition (Chen et al., 2015).

Interestingly, task-related and intrinsic network changes produced by OT showed a strikingly different sensitivity to repeated doses and OXTR genotype and there were no associations between resting state connectivity and either amygdala or behavioral responses to face emotions. However, for the resting state effects of OT there was no advantage of giving OT daily as opposed to every other day. Intrinsic networks may therefore be less sensitive to the effects of repeated OT administration or OXTR

genotype than those engaged by external social emotional stimuli, although arguably the effects of OT on neural processing during actual processing of social cues should be of greatest therapeutic relevance.

There are several limitations in the current study. Firstly, we only included male subjects to increase relevance to potential therapeutic use in autism and to avoid menstrual cycle effects. There is however increasing evidence for sex-dependent effects of OT, notably for amygdala responses (Gao et al., 2016; Jurek and Neumann, 2018; Lieberz et al., 2019; Luo et al., 2017) and also for rs53576 (Feng et al., 2015). Thus, females may show different responses to repeated doses of OT and associations with receptor genotype. Secondly, for the genotype analysis, subject numbers are relatively low for establishing robust associations. While treatment x genotype interactions only passed Bonferroni correction for arousal ratings, post-hoc tests for both behavioral and amygdala effects were highly significant. . The AA allele of rs53576 also occurs more frequently in Asian and Caucasian populations (Butovskaya et al., 2016). Finally, we only examined the effects of one dose and time course for the effects of OT and there may be dose-dependent and temporal variations. The 24IU dose and 45 min post-treatment time course used are the same as in many previous studies demonstrating both task and resting-state effects of OT (Kendrick et al., 2017) and maximal effects on reduced amygdala responses to fear faces occur with a 24IU dose from 45-75 min (Spengler et al., 2017). However, higher doses may produce different effects (Spengler et al., 2017) and a recent regional cerebral blood flow

study has reported reduced resting amygdala activity at shorter time points following 40IU intranasal OT (Martins et al., 2020).

In conclusion, the current study provides the first evidence for an important influence of OT dose frequency and receptor genotype on its modulation of neural and behavioral responses to emotional faces in healthy human subjects. Dose frequency therefore requires further empirical evaluation in patient populations given that it can critically determine treatment efficacy in clinical trials employing chronic administration.

Acknowledgement: We thank the reviewers and editor for their comments and suggestions for improving the manuscript. **Funding:** This project was supported by National Natural Science Foundation of China (NSFC) grant numbers 31530032 (KMK) and 91632117 (BB). **Author contributions:** JK and KMK designed the experiment. JK, YZ and CS carried out the experiment. JK, KMK, CM, FZ and BB analyzed the experiment and JK, KMK, CM and BB wrote the paper. All authors contributed to the conception of the study and approved the paper. **Competing interests:** The authors declare that they have no competing interests.

References

- Bales, K. L., Perkeybile, A. M., Conley, O. G., Lee, M. H., Guoynes, C. D., Downing, G. M., ... & Mendoza, S. P. (2013). Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. *Biological Psychiatry*, 74(3), 180-188.
- Benner, S., Aoki, Y., Watanabe, T., Endo, N., Abe, O., Kuroda, M., ... & Kasai, K. (2018). Neurochemical evidence for differential effects of acute and repeated oxytocin administration. *Molecular Psychiatry*, 1-11.
- Brüne, M. (2012). Does the oxytocin receptor polymorphism (rs2254298) confer 'vulnerability' for psychopathology or 'differential susceptibility'? Insights from evolution. *BMC Medicine*, 10(1), 38.
- Butovskaya, P. R., Lazebny, O. E., Sukhodolskaya, E. M., Vasiliev, V. A., Dronova, D. A., Fedenok, J. N., ... & Butovskaya, M. L. (2016). Polymorphisms of two loci at the oxytocin receptor gene in populations of Africa, Asia and South Europe. *BMC Genetics*, 17(1), 17.
- Cataldo, I., Azhari, A., & Esposito, G. (2018). A review of oxytocin and arginine-vasopressin receptors and their modulation of autism spectrum disorder. *Frontiers in Molecular Neuroscience*, 11, 27.
- Chen, F. S., Kumsta, R., Dvorak, F., Domes, G., Yim, O. S., Ebstein, R. P., & Heinrichs, M. (2015). Genetic modulation of oxytocin sensitivity: a pharmacogenetic approach. *Translational Psychiatry*, 5(10), e664-e664.

505 Cremers, H. R., Wager, T. D., & Yarkoni, T. (2017). The relation between statistical
506 power and inference in fMRI. *PloS one*, 12(11), e0184923.

507 Domes, G., Heinrichs, M., Glächer, J., Büchel, C., Braus, D. F., & Herpertz, S. C.
508 (2007). Oxytocin attenuates amygdala responses to emotional faces regardless
509 of valence. *Biological Psychiatry*, 62(10), 1187-1190.

510 Du, P., He, Z., Cai, Z., Hao, X., Dong, N., Yuan, W., ... & Tai, F. (2017). Chronic
511 central oxytocin infusion impairs sociability in mandarin voles. *Pharmacology*
512 *Biochemistry and Behavior*, 161, 38-46.

513 Eckstein, M., Becker, B., Scheele, D., Scholz, C., Preckel, K., Schlaepfer, T. E., ... &
514 Hurlemann, R. (2015). Oxytocin facilitates the extinction of conditioned fear
515 in humans. *Biological Psychiatry*, 78(3), 194-202.

516 Eckstein, M., Markett, S., Kendrick, K. M., Ditzen, B., Liu, F., Hurlemann, R., &
517 Becker, B. (2017). Oxytocin differentially alters resting state functional
518 connectivity between amygdala subregions and emotional control networks:
519 Inverse correlation with depressive traits. *Neuroimage*, 149, 458-467.

520 Eklund, A., Nichols, T. E., & Knutsson, H. (2016). Cluster failure: Why fMRI
521 inferences for spatial extent have inflated false-positive rates. *Proceedings of*
522 *the National Academy of Sciences*, 113(28), 7900-7905.

523 Fan, L., Li, H., Zhuo, J., Zhang, Y., Wang, J., Chen, L., ... & Fox, P. T. (2016). The
524 human brainnetome atlas: a new brain atlas based on connectional architecture.
525 *Cerebral Cortex*, 26(8), 3508-3526.

526 Feng, C., Lori, A., Waldman, I. D., Binder, E. B., Haroon, E., & Rilling, J. K. (2015).
527 A common oxytocin receptor gene (OXTR) polymorphism modulates
528 intranasal oxytocin effects on the neural response to social cooperation in
529 humans. *Genes, Brain and Behavior*, 14(7), 516-525.

530 Fischer, H., Wright, C.I., Whalen, P.J., McInerney, S.C., Shine, L.M., & Rauch, S.L.
531 (2003). Brain habituation during repeated exposure to fearful and neutral faces.
532 *Brain Research Bulletin* 59(5), 387-392.

533 Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. P., Frith, C. D., & Frackowiak,
534 R. S. (1994). Statistical parametric maps in functional imaging: a general
535 linear approach. *Human Brain Mapping*, 2(4), 189-210.

536 Gao, S., Becker, B., Luo, L., Geng, Y., Zhao, W., Yin, Y., ... & Kendrick, K.M.
537 (2016). Oxytocin, the peptide that bonds the sexes also divides them.
538 *Proceedings of the National Academy of Sciences*, 113(27), 7650-7654.

539 Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I.
540 B., ... & Einfeld, S. L. (2015). The effects of a course of intranasal oxytocin on
541 social behaviors in youth diagnosed with autism spectrum disorders: a
542 randomized controlled trial. *Journal of Child Psychology and Psychiatry*, 56(4),
543 444-452.

544 Guastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger,
545 H. M., ... & Banati, R. B. (2013). Recommendations for the standardisation of
546 oxytocin nasal administration and guidelines for its reporting in human
547 research. *Psychoneuroendocrinology*, 38(5), 612-625.

548 Guidi, J., Brakemeier, E. L., Bockting, C. L., Cosci, F., Cuijpers, P., Jarrett, R. B., ...
549 & Rief, W. (2018). Methodological recommendations for trials of
550 psychological interventions. *Psychotherapy and Psychosomatics*, 87(5),
551 276-284.

552 Halverson, T., Jarskog, L. F., Pedersen, C., & Penn, D. (2019). Effects of oxytocin on
553 empathy, introspective accuracy, and social symptoms in schizophrenia: A
554 12-week twice-daily randomized controlled trial. *Schizophrenia Research*, 204,
555 178-182.

556 Hennessey, T., Andari, E., & Rainnie, D. G. (2018). RDoC-based categorization of
557 amygdala functions and its implications in autism. *Neuroscience &*
558 *Biobehavioral Reviews*, 90, 115-129.

559 Huang, H., Michetti, C., Busnelli, M., Manago, F., Sannino, S., Scheggia, D., ... &
560 Scattoni, M. L. (2014). Chronic and acute intranasal oxytocin produce
561 divergent social effects in mice. *Neuropsychopharmacology*, 39(5),
562 1102-1114.

563 Jarskog, L. F., Pedersen, C. A., Johnson, J. L., Hamer, R. M., Rau, S. W., Elliott, T.,
564 & Penn, D. L. (2017). A 12-week randomized controlled trial of twice-daily
565 intranasal oxytocin for social cognitive deficits in people with schizophrenia.
566 *Schizophrenia Research*, 185, 88-95.

567 Jurek, B., & Neumann, I. D. (2018). The oxytocin receptor: from intracellular
568 signaling to behavior. *Physiological Reviews*, 98(3), 1805-1908.

569 Kendrick, K. M., Guastella, A. J., & Becker, B. (2017). Overview of human oxytocin
570 research. In Behavioral Pharmacology of Neuropeptides: Oxytocin (pp.
571 321-348). Springer, Cham. pp. 321–348.

572 Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., ... &
573 Meyer-Lindenberg, A. (2005). Oxytocin modulates neural circuitry for social
574 cognition and fear in humans. *Journal of Neuroscience*, 25(49), 11489-11493.

575 Koch, S.B.J., van Zuiden, M., Nawijn, L., Frijling, J.L., Veltman, D.J. (2016).
576 Intranasal oxytocin administration dampens amygdala reactivity towards
577 emotional faces in male and female PTSD patients.
578 *Neuropsychopharmacology*, 41, 1495-1504.

579 Lieberz, J., Scheele, D., Spengler, F. B., Matheisen, T., Schneider, L., Stoffel-Wagner,
580 B., ... & Hurlemann, R. (2019). Kinetics of oxytocin effects on amygdala and
581 striatal reactivity vary between women and men. *Neuropsychopharmacology*,
582 1-7.

583 Lee, M. R., Scheidweiler, K. B., Diao, X. X., Akhlaghi, F., Cummins, A., Huestis, M.
584 A., ... & Aeverbeck, B. B. (2018). Oxytocin by intranasal and intravenous
585 routes reaches the cerebrospinal fluid in rhesus macaques: determination using
586 a novel oxytocin assay. *Molecular Psychiatry*, 23(1), 115-122.

587 Lohse, M. J., & Hofmann, K. P. (2015). Spatial and Temporal Aspects of Signaling
588 by G-Protein–Coupled Receptors. *Molecular Pharmacology*, 88(3), 572-578.

589 Luo, L., Becker, B., Geng, Y., Zhao, Z., Gao, S., Zhao, W., ... & Hu, J. (2017).
590 Sex-dependent neural effect of oxytocin during subliminal processing of
591 negative emotion faces. *Neuroimage*, 162, 127-137.

592 Martins, D.A., Mazibuko, N, Zelaya, F., Vasilakopoulou, S., Loveridge, J., Oates,
593 U., ... & Paloyelis, Y. (2020). Effects of route of administration on
594 oxytocin-induced changes in regional cerebral blood flow in humans. *Nature*
595 *Communications* doi: 10.1038/s41467-020-14845-5

596 Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011). Oxytocin and
597 vasopressin in the human brain: social neuropeptides for translational
598 medicine. *Nature Reviews Neuroscience*, 12(9), 524-538.

599 Montag, C., Sindermann, C., Melchers, M., Jung, S., Luo, R., Becker, B., ... &
600 Kendrick, K. M. (2017). A functional polymorphism of the OXTR gene is
601 associated with autistic traits in Caucasian and Asian populations. *American*
602 *Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 174(8),
603 808-816.

604 Mueller, K., Lepsien, J., Möller, H. E., & Lohmann, G. (2017). Commentary: Cluster
605 failure: Why fMRI inferences for spatial extent have inflated false-positive
606 rates. *Frontiers in Human Neuroscience*, 11, 345.

607 Neumann, I. D., & Slattery, D. A. (2016). Oxytocin in general anxiety and social fear:
608 a translational approach. *Biological Psychiatry*, 79(3), 213-221.

609 Paloyelis, Y., Doyle, O. M., Zelaya, F. O., Maltezos, S., Williams, S. C., Fotopoulou,
610 A., & Howard, M. A. (2016). A spatiotemporal profile of in vivo cerebral
611 blood flow changes following intranasal oxytocin in humans. *Biological*
612 *Psychiatry*, 79(8), 693-705.

613 Parker, K. J., Garner, J. P., Libove, R. A., Hyde, S. A., Hornbeak, K. B., Carson, D.
614 S., ... & Hardan, A. Y. (2014). Plasma oxytocin concentrations and OXTR
615 polymorphisms predict social impairments in children with and without autism
616 spectrum disorder. *Proceedings of the National Academy of Sciences*, 111(33),
617 12258-12263.

618 Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). Seven-transmembrane
619 receptors. *Nature Reviews Molecular Cell Biology*, 3(9), 639-650.

620 Poldrack, R. A., Baker, C. I., Durnez, J., Gorgolewski, K. J., Matthews, P. M.,
621 Munafò, M. R., ... & Yarkoni, T. (2017). Scanning the horizon: towards
622 transparent and reproducible neuroimaging research. *Nature Reviews*
623 *Neuroscience*, 18(2), 115.

624 Quintana, D. S., Rokicki, J., van der Meer, D., Alnæs, D., Kaufmann, T.,
625 Córdova-Palomera, A., ... & Westlye, L. T. (2019). Oxytocin pathway gene
626 networks in the human brain. *Nature Communications*, 10(1), 1-12.

627 Quintana, D.S., Westlye, L.T., Alnaes, D., Rustan, Ø.G., Kaufmann, T.,...&
628 Andreassen, O.A. (2016). Low dose intranasal oxytocin delivered with Breath
629 Powered device dampens amygdala response to emotional stimuli: A

630 peripheral effect-controlled within-subjects randomized dose-response fMRI
631 trial. *Psychoneuroendocrinology*, 69, 180-188.

632 Russell, J. A. (2018). 50 years of advances in neuroendocrinology. *Brain and*
633 *Neuroscience Advances*, 2, 1-20.

634 Smith, M. P., Ayad, V. J., Mundell, S. J., McArdle, C. A., Kelly, E., & López Bernal,
635 A. (2006). Internalization and desensitization of the oxytocin receptor is
636 inhibited by Dynamin and clathrin mutants in human embryonic kidney 293
637 cells. *Molecular Endocrinology*, 20(2), 379-388.

638 Spengler, F. B., Schultz, J., Scheele, D., Essel, M., Maier, W., Heinrichs, M., &
639 Hurlemann, R. (2017). Kinetics and dose dependency of intranasal oxytocin
640 effects on amygdala reactivity. *Biological Psychiatry*, 82(12), 885-894.

641 Sripada, C. S., Phan, K. L., Labuschagne, I., Welsh, R., Nathan, P. J., & Wood, A. G.
642 (2013). Oxytocin enhances resting-state connectivity between amygdala and
643 medial frontal cortex. *International Journal of Neuropsychopharmacology*,
644 16(2), 255-260.

645 Stoop, R. (2012). Neuromodulation by oxytocin and vasopressin. *Neuron*, 76(1),
646 142-159.

647 Striepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wüllner, U., Maier, W., &
648 Hurlemann, R. (2013). Elevated cerebrospinal fluid and blood concentrations
649 of oxytocin following its intranasal administration in humans. *Scientific*
650 *Reports*, 3, 3440.

651 Terenzi, M. G., & Ingram, C. D. (2005). Oxytocin-induced excitation of neurones in
652 the rat central and medial amygdaloid nuclei. *Neuroscience*, 134(1), 345-354.

653 Wang, D., Yan, X., Li, M., & Ma, Y. (2017). Neural substrates underlying the effects
654 of oxytocin: a quantitative meta-analysis of pharmaco-imaging studies. *Social*
655 *Cognitive and Affective Neuroscience*, 12(10), 1565-1573.

656 Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., ... &
657 Kasai, K. (2015). Clinical and neural effects of six-week administration of
658 oxytocin on core symptoms of autism. *Brain*, 138(11), 3400-3412.

659 Wright, C. I., Fischer, H., Whalen, P. J., McInerney, S. C., Shin, L. M., Rauch, S. L.
660 (2001). Differential prefrontal cortex and amygdala habituation to repeatedly
661 presented emotional stimuli. *Neuroreport*, 12, 379-383.

662 Yamasue, H., Okada, T., Munosue, T., Kuroda, M., Fujioka, T., Uno, Y., ... &
663 Yoshimura, Y. (2018). Effect of intranasal oxytocin on the core social
664 symptoms of autism spectrum disorder: a randomized clinical trial. *Molecular*
665 *Psychiatry*, 1-10.

666 Chao-Gan, Y., & Yu-Feng, Z. (2010). DPARSF: a MATLAB toolbox for “pipeline”
667 data analysis of resting-state fMRI. *Frontiers in Systems Neuroscience*, 4.

668 Yang, S., Dong, X., Guo, X., Han, Y., Song, H., Gao, L., ... & Zhang, X. (2017).
669 Serum oxytocin levels and an oxytocin receptor gene polymorphism
670 (rs2254298) indicate social deficits in children and adolescents with autism
671 spectrum disorders. *Frontiers in Neuroscience*, 11, 221.

672 Young, L. J., & Barrett, C. E. (2015). Can oxytocin treat autism? *Science*, 347(6224),
673 825-826.

674 Zhang, Z., & Yuan, K.H. (2018). Practical Statistical Power Analysis Using
675 Webpower and R (Eds). *Granger*, IN: ISDSA Press.

676 Zhao, W., Becker, B., Yao, S., Ma, X., Kou, J., & Kendrick, K. M. (2019). Oxytocin
677 enhancement of the placebo effect may be a novel therapy for working
678 memory impairments. *Psychotherapy and Psychosomatics*, 88(2), 125-126.

679 Zhao, Z., Yao, S., Li, K., Sindermann, C., Zhou, F., Zhao, W., ... & Becker, B. (2019).
680 Real-time functional connectivity-informed neurofeedback of
681 amygdala-frontal pathways reduces anxiety. *Psychotherapy and*
682 *Psychosomatics*, 88(1), 5-15.

683

684

Figure Legends




Fig.1 The effect of intranasal oxytocin (OT) treatment on neural responses to faces. (a)

The mask of right amygdala from the Brainnetome atlas (Fan et al., 2016)(b-e) Post

hoc analysis on extracted parameter estimates from the right amygdala mask for all

face emotion categories on the 1st and 5th days.# p < 0.1, * p < 0.05, ** p < 0.01,

two-tailed. Bars depict standard errors.




Fig.2 The effects of oxytocin (OT) on arousal and intensity ratings for face emotions.

(a) OT decreased arousal and intensity ratings of fear faces on both the 1st and the 5th days of treatment in the group receiving OT on alternate days (OT₃) compared with placebo (PLC) and ratings were significantly reduced on day 5 relative to day 1. The group receiving OT every day (OT₅) did not show significant effects on either day 1 or 5. No effects of OT on ratings for (b) anger, (c) happy and (d) happy face emotions.

p < 0.1, * p < 0.05, ** p < 0.01 two-tailed, Bars depict standard errors.




Fig.3 Associations between intensity and arousal ratings of fear faces and amygdala

activation in the placebo (PLC) and two OT treatment groups (OT₃ and OT) on days 1

and 5. The magnitude of right amygdala (from the Brainnetome atlas) responses was

positively correlated with arousal and intensity ratings in the PLC group on day 1 but

not in the OT groups. There was a similar trend on day 5. * $p < 0.05$. ** $p < 0.01$

(Pearson Correlation).




Fig.4 The effects of oxytocin (OT) on resting state functional connectivity (a) schematic visualization of the identified functional pathway between the right amygdala and anterior prefrontal cortex (replicating Eckstein et al., 2017). (b) Seed to whole-brain analysis of functional connectivity (FC, seed region right amygdala, 6mm sphere, $x=18$, $y=-7$, $z=-16$) revealed significantly increased functional connectivity between right amygdala and anterior prefrontal cortex ($p_{FWE}=0.039$, $x=-36$, $y=59$, $z=-7$) in both OT treatment groups (OT₃ and OT₅) on both, days 1 and 5 relative to placebo (PLC). Line graphs depict the extracted parameter estimates from right amygdala connectivity with anterior prefrontal cortex ($M \pm SE$). * $p < 0.05$, ** $p < 0.01$ two-tailed. Bars indicate standard errors.




Fig.5 Influence of oxytocin (OT) receptor genotype on the effects of intranasal OT on right amygdala and behavioral responses to face emotions (n = 111 subjects). (a) for rs 53576 only G-non carriers (i.e. AA) showed reduced amygdala responses to faces (PLC, $n_{G+}=15$, $n_{G-}=21$; OT₃, $n_{G+}=17$, $n_{G-}=24$; OT₅, $n_{G+}=20$, $n_{G-}=14$); (b) for rs2254298 only A-carriers (i.e. AA and AG) in the groups with intranasal oxytocin (OT) treatment showed reduced amygdala responses to faces (PLC, $n_{A+}=20$, $n_{A-}=16$; OT₃, $n_{A+}=23$, $n_{A-}=18$; OT₅, $n_{A+}=20$, $n_{A-}=14$); (c) for rs2254298 only A-carriers (i.e. AA and AG) in the groups with intranasal oxytocin (OT) treatment showed reduced emotional arousal ratings ** $p < 0.01$, two-tailed t-test (Bonferroni corrected significance threshold of $p = 0.0125$). Bars indicate standard errors.